Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07543965 · ClinicalTrials.gov registry record
Cohort of Repeat Donor Experiences (CORE) Study
A clinical trial, sponsored by Westat.
- Not yet
- Registry status
- 2,090
- Enrollment target
NCT07543965: Clinical Trial study, sponsored by Westat.
NCT07543965 is a clinical trial that has not yet begun recruiting, run by Westat. The registered enrollment target is 2,090 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07543965 has not yet begun recruiting, sponsored by Westat.
- NOT YET RECRUITING
- Registry status
- 2,090 participants
- Enrollment target
Study Summary
The Plasma Protein Therapeutics Association (PPTA) sponsors the Cohort of Repeat Donor Experiences (CORE) Study. This is a prospective, observational cohort study that will follow Source Plasma donors for up to 2 years during the main study (anticipated to begin in summer 2026) and up to 3 months during the pilot launching in mid-March 2026. This study aims to confirm a lack of negative health effects Source Plasma donors may experience as a result of frequent plasmapheresis. The study will use data obtained through self-report surveys for the duration of the study along with periodic whole blood sample collections to test for CRP, ferritin, and IgG.
Primary Outcome
To investigate the direct effects of the frequency, recency, and volume of plasmapheresis on biochemical markers and evaluate their role as mediators in the relationship between plasmapheresis and health outcomes.
Interventions
- PROCEDURE Plasmapheresis Procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,090 participants |
| Start Date | 2026-04-06 |
| Est. Completion | 2029-04-30 |
What is known before NCT07543965 opens enrollment
NCT07543965 is an observational study that tracks outcomes without assigning an intervention. Its 2,090 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Plasmapheresis Procedure is the first listed.
NCT07543965 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07543965 about?
NCT07543965 is a clinical study titled "Cohort of Repeat Donor Experiences (CORE) Study". The Plasma Protein Therapeutics Association (PPTA) sponsors the Cohort of Repeat Donor Experiences (CORE) Study. This is a prospective, observational cohort study that will follow Source Plasma donors for up to 2 years during the main study (anticipated to begin in summer 2026) and up to 3 months du...
What is the current status of trial NCT07543965?
This trial is currently not yet recruiting. The enrollment target is 2,090 participants. The study started on 2026-04-06. Estimated completion is 2029-04-30.
What interventions are being tested in trial NCT07543965?
The interventions under investigation include: Plasmapheresis Procedure (PROCEDURE).
Who is sponsoring clinical trial NCT07543965?
This trial is sponsored by Westat, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04649242 · 2,100 participants · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- NCT05206331 · 2,100 participants · Phase 4
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
- NCT05270499 · 2,100 participants
Aveir VR Real-World Evidence Post-Approval Study
- NCT06324981 · 2,100 participants · NA
Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI